Table 1.
Baseline characteristics of AUMC (discovery cohort) and TCGA database.
| Characteristics | AUMC (n = 107) | TCGA (n = 77) | p Value |
|---|---|---|---|
| Sex | |||
| Male/female (no.) | 95/12 | 66/11 | |
| Male/female (%) | 89/11 | 86/14 | 0.65 † |
| Age | |||
| Median (IQR) years | 66.7 (15.7) years | 68.0 (19.0) years | 0.65 ^ |
| Year of diagnosis | - | ||
| ’98/’99/’00/’01/’04/’05/’06/’07/’08/’09/’10/ | 0/0/0/0/0/0/0/0/0/0/0/ | 1/2/8/11/5/3/5/2/1/3/8/ | |
| ’11/‘12/’13/’14/’15/’16/’17/NA (no.) | 0/16/20/16/27/22/6/0 | 5/12/6/0/0/0/0/5 | |
| AJCC Stage | 0.00 ** | ||
| I/II/III/IV/NA (no.) | 0/27/65/12/3 | 10/22/32/10/3 | |
| I/II/III/IV (%) | 0/26/63/12 | 14/30/43/14 | |
| Clinical T stage at baseline | - | ||
| Tx/T0/T1/T2/T3/T4/NA (no.) | 4/0/2/19/78/4/0 | 2/0/1/2/13/59 | |
| Tx/T0/T1/T2/T3/T4 (%) | 4/0/2/18/73/4 | - | |
| Clinical T stage at baseline in patients treated with nC(R)T/surgery with or without adjuvant therapy | NA | NA | |
| Tx/T0/T1/T2/T3/T4/NA (no.) | 3/0/1/11/51/2/0 | ||
| Tx/T0/T1/T2/T3/T4 (%) | 4/0/1/16/75/3 | ||
| Histologic grade | 0.00 * | ||
| G1/G2/G3/NA (no.) | 23/33/46/5 | 1/27/24/25 | |
| G1/G2/G3 (%) | 23/32/45 | 2/52/46 | |
| Lauren classification | NA | NA | |
| Intestinal/Diffuse/Mixed/NA (no.) | 70/14/22/1 | ||
| Intestinal/Diffuse/Mixed (%) | 66/13/21 | ||
| Signet ring cells | NA | NA | |
| present/absent/NA (no.) | 25/56/26 | ||
| present/absent (%) | 31/69 | ||
| Patients per initial treatment strategy n(%)If applicable also Mandard (m) scorem1/m2/m3/m4/m5/NA (no.) | |||
| nCRT CROSS /surgery | 46(43%) 6/9/17/12/0/2 | 0 | - |
| nCRT CROSS/surgery/adjuvant SOX | 10 (9%) 3/5/2/0/0/0 | 0 | - |
| nCRT CROSS+TRAP/surgery | 4 (4%) 1/1/2/0/0/0 | 0 | - |
| nCRT CROSS/no surgery | 7 (7%) | 0 | - |
| nCT EOX /surgery/adjuvant EOX | 4 (4%) 2/0/0/0/1/1 | 0 | - |
| nCT EOX/surgery | 3 (3%) 0/1/0/2/0/0 | 0 | - |
| nCT ECC/surgery/adjuvant ECC | 1 (1%) 0/0/0/1/0/0 | 0 | - |
| only surgery | 1 (1%) | 0 | - |
| dCRT carboplatin/paclitaxel/no surgery | 16 (15%) | 0 | - |
| palliative therapy | 13 (12%) | 0 | - |
| No treatment | 2 (2%) | 0 | - |
| Surgery, priorly treated with radiation and chemotherapy (but no neo-adjuvant therapy) | 0 | 2 (3%) | - |
| No neo-adjuvant therapy, surgery | 0 | 65 (84%) | - |
| No neo-adjuvant therapy, no surgery | 0 | 10 (13%) | - |
| Mandard score in all patients treated with nC(R)T/surgery with or without adjuvant therapy (n = 70) | NA | NA | |
| 1/2/3/4/5/NA (no.) | 12/16/21/15/1/3 | ||
| 1/2/3/4/5 (%) | 18/25/32/23/2 | ||
| T stage resection specimen in all patients treated with nC(R)T/surgery with or without adjuvant therapy (n = 70) | NA | NA | |
| Tx/T1/T2/T3/T4/NA (no.) | 12/14/12/26/2/2 | ||
| Tx/T1/T2/T3/T4 (%) | 18/21/18/39/3 |
† Fisher’s exact test two-sided; ^ Mann-Whitney-Wilcoxon test (Age is not normally distributed according to QQ-plot and histogram); * Chi square test; ** Chi square test with simulated p-value (2000 replicates); Number (no.); InterQuartile Range (IQR); Not Available (NA); neo-adjuvant Chemo(Radio)Therapy (nC(R)T); neo-adjuvant ChemoRadioTherapy with carboplatin and paclitaxel + 41.4 Gy according to the CROSS trial (nCRT CROSS); adjuvant therapy with S-1 and oxaliplatin (adjuvant SOX); neo-adjuvant trastuzumab and pertuzumab in HER2 positive EAC (TRAP); neo-adjuvant chemotherapy with epirubicin, oxaliplatin and capecitabin (nCT EOX); adjuvant chemotherapy with epirubicin, oxaliplatin and capecitabin (adjuvant EOX); adjuvant chemotherapy with epirubicin, cisplatin and capecitabin (adjuvant ECC); definitive ChemoRadioTherapy with carboplatin and paclitaxel + 41.4 Gy (dCRT carbo/pac). TCGA AJCC Stage derived from Neoplasm.Disease.Stage.American.Joint.Committee.on.Cancer.Code (equal to clinical stage in biolinks file) and Neoplasm.Disease.Stage.American.Joint.Committee.on.Cancer.Code.1 (equal to pathological stage in biolinks file) from Cbioportal file. TCGA Clinical T stage at baseline derived from stage_event_tnm_categories and stage_event_clinical_stage in biolinks file.